Dopamine receptors - Physiological understanding to therapeutic intervention potential

Pharmacology and Therapeutics

Volumn 84, Issue 2, 1999, Pages 133-156

  Emilien, Gérard ^a   Maloteaux, Jean Marie ^a   Geurts, Muriel ^a   Hoogenberg, Klaas ^b   Cragg, Stephanie ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Dopamine receptors; Heart failure; Migraine; Neuroleptic; Parkinson's disease; Renal failure; Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; ERGOT DERIVATIVE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; PERGOLIDE; RACLOPRIDE; SELEGILINE;

DEPRESSION; DRUG DEPENDENCE; GILLES DE LA TOURETTE SYNDROME; HEART FAILURE; HUMAN; KIDNEY FAILURE; MANIA; MIGRAINE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; KIDNEY FAILURE; NERVOUS SYSTEM DISEASES; RECEPTORS, DOPAMINE;

EID: 0032829657     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00029-7     Document Type: Review

References (256)

1. 1 receptor blockade stereospecifically impairs the acquisition of drug-conditioned place-preference and place aversion. Behav Pharmacol. 5:1994;555-569.
2. 1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest. 97:1996;2283-2288.
3. 1 receptors. Eur J Pharmacol. 197:1991;221-223.
4. Amenta F., Gallo P., Rossodivita A., Ricci A. Radioligand binding and autoradiographic analysis of dopamine receptors in the human heart. Naunyn Schmiedebergs Arch Pharmacol. 347:1993;147-154.
5. Amery W.K., Waelkens J. Prevention of the last chance. An alternative pharmacologic treatment of migraine Headache. 23:1983;37-38.
6. Andringa G., Vermeulen R.J., Drukarch B., Stoof J.C., Cools A.R. Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease. Adv Pharmacol. 42:1998;792-795.
7. Aono J., Mamiya K., Ueda W., Manabe M. Effect of dopamine administration on ICG-disappearance rate during prone position anesthesia. [Japanese]. Masui Jpn J Anesthesiol. 43:1994;1857-1860.
8. Apter A., Pauls D.L., Bleich A., Zohar A.H., Kron S., Ratzoni G., Dycian A., Kotler M., Weizman A., Gadot N., Cohen D.J. An epidemiologic study of Gilles de la Tourette's syndrome in Israel. Arch Gen Psychiatry. 50:1993;734-738.
9. Asico L.D., Fuchs S., Accili D., Carey R.M., Eisner G.M., Jose P.A. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Am Soc Nephrol. 8:1997;295A.
10. 3 receptor gene products renin-dependent hypertension. J Clin Invest. 102:1998;493-498.
11. 2-receptor mRNA is differentially regulated by dopaminergic agents in rat anterior and neurointermediate pituitary. Mol Cell Endocrinol. 67:1989;101-105.
12. Baldwin J., Henderson A., Hickman P. Effects of post-operative low-dose dopamine on renal function after elective major vascular surgery. Ann Intern Med. 120:1994;744-747.
13. Baronti F., Mouradian M.M., Conant K.E., Giuffra M., Brughitta G., Chase T.N. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology. 42:1992;1241-1243.
14. Bassareo V., Tanda G., Petromilli P., Giua C., Di Chiara G. Non-psychostimulant drugs of abuse and anxiogenic drugs activate with differential selectivity dopamine transmission in the nucleus accumbens and in the medial prefrontal cortex of the rat. Psychopharmacology. 124:1996;296-299.
15. Bateman D.E. A simple model to explain the motor fluctuations seen in Parkinson's disease. J Neurol Neurosurg Psychiatry. 59:1995;555.
16. Bell R., Montoya D., Shuaib A., Lee M.A. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 19:1990;1079-1082.
17. 4 dopamine receptor gene and measures of novelty seeking. Nat Genet. 12:1996;81-84.
18. Blin O., Azulay J., Masson G., Aubrespey G., Serratrice G. Apomorphine-induced yawning in migraine patients. enhanced responsiveness Clin Neuropharmacol. 14:1991;91-95.
19. Boothman B.R., Spokes E.G. Pharmacokinetic data for ropinirole. Lancet. 336:1990;316-317.
20. Boulay D., Duterte-Boucher D., Leroux-Nicollet I., Naudon L., Costentin J. Locomotor sensitization to [D-Trp(11)]neurotensin after repeated injections of the dopamine uptake inhibitor GBR12783 in rats. J Pharmacol Exp Ther. 278:1996;330-337.
21. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R.A., Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl. 46:1995;15-31.
22. Brefel C., Thalamas C., Rayet S., Lopez-Gil A., Fitzpatrick K., Bullman S., Citerone D.R., Taylor A.C., Montastruc J.L., Rascol O. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol. 45:1998;412-415.
23. Bristow L.J., Kramer M.S., Kulagowski J., Patel S., Ragan C.I., Seabrook G.R. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. 18:1997;186-188.
24. Brooks D.J., Abbott R.J., Lees A.J., Martignon E., Philcox D.V., Rascol O., Roos R.A., Sagar H.J. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol. 21:1998;101-107.
25. Brown A.S., Gershon S. Dopamine and depression. J Neural Transm Gen Sect. 91:1993;75-109.
26. Burns R.S., Calne D.B. Disposition of dopaminergic ergot compounds following oral administration. Calne D.B., Horowski R., McDonald R.J., Wuttke W. Lisuride and Other Dopamine Agonists. Basic Mechanisms and Endocrine and Neurological Effects:1983;153-160 Raven Press, New York.
27. Burton K., Calne D.B. What is the cause? Stern G.M. Parkinson's Disease. 1990;269-294 Chapman and Hall Medical, Oxford.
28. Cameron J.D., Lane P.L., Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Accid Emerg Med. 2:1995;597-602.
29. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex. evidence that dopamine is taken up in vivo by noradrenergic terminals J Neurochem. 55:1990;1067-1070.
30. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
31. Cerbo R., Barbanti P., Buzzi M.G., Fabbrini G., Brusa L., Roberti C., Zanette E., Lenzi G.L. Dopamine hypersensitivity in migraine. Role of the apomorphine test Clin Neuropharmacol. 20:1997;36-41.
32. Chen C.J., Lokhandwala M.F. Dopamine receptor agonists in cardiovascular pharmacology. Indian J Pharmacol. 24:1992;72-81.
33. Chen C.J., Beach R.E., Lokhandwala M.F. Dopamine fails to inhibit renal tubular sodium pump in hypertensive rats. Hypertension. 21:1993;364-372.
34. Chertow G.M., Sayegh M.H., Allgren R.L., Lazarus J.M. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Am J Med. 101:1996;49-53.
35. Civelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol. 32:1993;281-307.
36. 4.4 receptors in functional studies using microphysiometry. Br J Pharmacol. 119(suppl.):1997;346P.
37. Compton C., Rizk I., Regauer S., Burd E., Holaday J. The effect of bromocryptine-induced hypoprolactinaemia on xenograft and allogenic graft survival in a mouse model. J Burn Care Rehabil. 15:1994;393-400.
38. Coppola M., Yealy D.M., Leibold R.A. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 26:1995;541-546.
39. Coward D.M., Dixon A.K., Urwyler S., White T.G., Enz A., Karobath M., Shearman G. Partial dopamine agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther. 252:1990;279-285.
40. Cragg S.J., Greenfield S.A. Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J Neurosci. 17:1997;5738-5746.
41. Critchley P., Grandas Perez F., Quinn N., Coleman R., Parkes D., Marsden C.D. Psychosis and the lisuride pump. Lancet. 2:1986;349.
42. 1 dopamine receptor. Nature. 347:1990;72-76.
43. Dei Cas L., Bolognesi R., Cucchini F., Fappani A., Riva S., Visioli O. Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy. J Cardiovasc Pharmacol. 5:1983;249-253.
44. Del Zompo M., Lai M., Loi V., Pisano M.R. Dopamine hypersensitivity in migraine. Role in apomorphine syncope Headache. 35:1995;222-224.
45. De Montis M.G., Devoto P., Gessa G.L., Porcella A., Serra G., Tagliamonte A. Possible role of DA receptors in the mechanism of action of antidepressants. Gessa G.L., Serra G. Dopamine and Mental Depression. 1990;147-157 Pergamon Press, Oxford.
46. Denton M.D., Chertow G.M., Brady H.R. "Renal-dose" dopamine for the treatment of acute renal failure. scientific rationale, experimental studies and clinical trials Kidney Int. 49:1996;4-14.
47. Devine D.P., Leone P., Pocock D., Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release. in vivo microdialysis studies J Pharmacol Exp Ther. 266:1993;1236-1246.
48. Diana M. Drugs of abuse and dopamine cell activity. Adv Pharmacol. 42:1998;998-1001.
49. Di Chiara G., Tanda G., Cadoni C., Acquas E., Bassareo V., Carboni E. Homologies and differences in the action of drugs of abuse and a conventional reinforcer (food) on dopamine transmission. an interpretative framework of the mechanism of drug dependence Adv Pharmacol. 42:1998;983-987.
50. Dooley M., Markham A. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging. 12:1998;495-514.
51. Dragatakis L.N., Kuchel O., Larochelle P. Cardiovascular effects of bromocriptine in man. Clin Pharmacol Ther. 27:1980;250-251.
52. Duncker D.J., van Meegen J.R., Verdouw P.D. Cardiovascular actions of the dopamine receptor agonist Z1046 in swine. Cardiovasc Drugs Ther. 11:1997;537-545.
53. 4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet. 12:1996;78-80.
54. +-ATPase. Kidney Int. 52:1997;742-747.
55. Elsworth J., Roth R. Dopamine autoreceptor pharmacology and function. Recent insights Neve K., Neve R. The Dopamine Receptors. 1996;223-265 Humana Press, Totowa.
56. Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 231:1986;258-261.
57. Feinberg M., Carroll B.J. Effects of dopamine agonists and antagonists in Tourette's disease. Arch Gen Psychiatry. 36:1979;979-985.
58. Felder C.C., Jose P.A., Axelrod J. The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J Pharmacol Exp Ther. 248:1989;171-175.
59. Felder C.C., Campbell T., Albrecht F., Jose P.A. Dopamine inhibits Na-H exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol. 259:1990;F297-F303.
60. 3 receptor agonist 7-OH-DPAT in rats. Pharmacol Res. 32:1995;63-68.
61. Fishburn C.S., Elazar Z., Fuchs S. Differential glycosylation and intracellular trafficking for the long and short isoforms of the D2 dopamine receptor. J Biol Chem. 270:1995;29819-29824.
62. Fisher H. A new approach to emergency department therapy of migraine headache with intravenous haloperidol. a case series J Emerg Med. 13:1995;119-122.
63. Fisher L.J., Gage F.H. Novel therapeutic direction for Parkinson's disease. Mol Med Today. 1:1995;181-187.
64. Flancbaum L., Choban P.S., Dasta J.F. Quantitative effects of low-dose dopamine on urine output in oliguric surgical intensive care unit patients. Crit Care Med. 22:1994;61-68.
65. Fleckenstein A.E., Kopajtic R.A., Boja J.W., Carroll F.I., Kuhar M.J. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. Eur J Pharmacol. 311:1996;109-114.
66. Fowler J.S., Volkow N.D., Logan J., Gatley J.S., Pappas N., King P., Ding Y.S., Wang G.J. Measuring dopamine transporter occupancy by cocaine in vivo. radiotracer considerations Synapse. 28:1998;111-116.
67. Francis G.S., Parks R., Cohn J.N. The effects of bromocriptine in patients with congestive heart failure. Am Heart J. 106:1983;100-106.
68. Francis G.S., Wilson B.C., Rector T.S. Hemodynamic, renal and neurohumoral effects of selective oral DA1 receptor agonist (Fenoldopam) in patients with congestive heart failure. Am Heart J. 116:1988;473-479.
69. Frankel J.P., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 53:1990;96-101.
70. Fujiwara Y., Yamaguchi K., Tanaka Y., Tomita H., Shiro Y., Kashihara K., Sato K., Kuroda S. Polymorphism of dopamine receptors and transporter genes in neuropsychiatric diseases. Eur Neurol. 38:1997;6-10.
71. Gancher S.T., Nutt J.G., Woodward W.R. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology. 37:1987;940-944.
72. Garris P.A., Walker Q.D., Wightman R.M. Dopamine release and uptake rate both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 753:1997;225-234.
73. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
74. Germann R., Haisjackl M., Hasibeder W., Sparr H., Luz G., Plattner R., Pernthaler H., Friesenecker B., Falk M. Dopamine and mucosal oxygenation in the porcine jejunum. J Appl Physiol. 77:1994;2845-2852.
75. Girbes A.R.J., Hoogenberg K. The use of dopamine and norepinephrine in the ICU. Vincent J.-L. Yearbook Intensive Care and Emergency Medicine 1998. 1998;178-187 Springer-Verlag Berlin and Heidelberg GmbH & Co. KG, Berlin.
76. Girbes A.R.J., Van Veldhuisen D.J., Smit A.J. Nouveaux agonistes de la dopamine en thérapie cardiovasculaire. Presse Med. 21:1992;1287-1291.
77. Girbes A.R.J., Lieverse A.G., Smit A.J., Van Veldhuisen D.J., Zwaveling J.H., Meijer S., Reitsma W.D. Lack of specific renal hemodynamic effects of different doses of dopamine in mechanically ventilated patients after infrarenal aortic surgery. Br J Anaesth. 77:1996;753-757.
78. Girbes A.R.J., Hoogenberg K., Smit A.J. Renal dopamine. Br J Anaesth. 79:1997;263-264.
79. Giros B., Sokoloff B.P., Martres M.P., Riou J.F., Emorine L.J., Schwartz J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 342:1989;923-926.
80. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
81. Goldberg L.I. Cardiovascular and renal actions of dopamine. potential clinical applications Pharmacol Rev. 24:1972;1-29.
82. Goldberg L.I., Bass A.S. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride. Am J Cardiol. 62:1988;37C-40C.
83. Goldberg L.I., Hsieh Y.Y., Resnekov L. Newer catecholamines for treatment of heart failure and shock. an update on dopamine and a first look at dobutamine Prog Cardiovasc Dis. 4:1977;327-340.
84. 2 receptor gene is located on chromosome 11 at q22-23 and identifies a Taq RFLP. Am J Hum Genet. 45:1989;778-785.
85. Hammerstad J.P., Woodward W.R., Gliessman P., Boucher B., Nutt J.G. The pharmacokinetics of L-dopa in plasma and CSF of the monkey. Bernardi G., Carpenter M.B., Di Chiara G., Morelli M. The Basal Ganglia III. 1990;683-688 Plenum Press, New York.
86. Harder S., Baas H., Demisch L., Simon E. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia. Int J Clin Pharmacol Ther. 36:1998;355-361.
87. Hely M.A., Morris J.G., Reid W.G., O'Sullivan D.J., Williamson P.M., Rail D., Broe G.A., Margrie S. The Sydney Multicentre Study of Parkinson's disease. a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa J Neurol Neurosurg Psychiatry. 57:1994;903-910.
88. Hemmer M., Suter P.M. Treatment of cardiac and renal effects of PEEP with dopamine in patients with acute respiratory failure. Anesthesiology. 50:1979;399-403.
89. Henderson I.S., Beattie T.J., Kennedy A.C. Dopamine hydrochloride in oliguric states. Lancet. 2:1980;827-828.
90. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res. 648:1994;222-228.
91. Hoehn M.M., Yahr M.D. Parkinsonism. onset, progression and mortality Neurology. 17:1967;427-442.
92. Hoogenberg K., Smit A.J., Girbes A.R.J. Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med. 26:1998;260-265.
93. Hubble J.P., Koller W.C., Cutler N.R., Sramek J.J., Friedman J., Goetz C., Ranhosky A., Korts D., Elvin A. Pramipexole in patients with early Parkinson's disease. Clin Pharmacol. 18:1995;338-347.
94. Iserson K.V. Parenteral chlorpromazine treatment of migraine. Ann Emerg Med. 12:1983;756-758.
95. Ison P.J., Peroutka S.J. Neurotransmitter receptor binding predicts antiemetic efficacy and side effects. Cancer Treat Rep. 70:1986;637-641.
96. 3H]dopamine uptake in vitro in rat nucleus accumbens but not in striatum. Brain Res. 531:1990;338-341.
97. Izenwasser S., Cox B.M. Inhibition of dopamine uptake by cocaine and nicotine. tolerance to chronic treatments Brain Res. 573:1992;119-125.
98. Jenner P. The rational use of dopamine agonists in Parkinson's disease. Neurology. 45(suppl. 3):1995;S6-S12.
99. Jones J., Sklar D., Dougherty J., White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 261:1989;1174-1176.
100. Jose P.A., Raymond M.D., Bates A., Aperia A., Felder R.A., Carey R.M. The renal dopamine receptors. J Am Soc Nephrol. 2:1992;1265-1278.
101. Joyce J.N., Marshall J.F. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen. localization to intrinsic neurons and not to neocortical afferents Neuroscience. 20:1987;773-795.
102. Kadieva V.S., Friedman L., Margolius L.P., Jackson S.A., Morell D.F. The effect of dopamine on graft function in patients undergoing renal transplantation. Anesth Analg. 76:1993;362-365.
103. Kapusta D.R., Robie N.W. Plasma dopamine in regulation of canine renal blood flow. Am J Physiol. 255:1988;R379-R387.
104. Karlsson P., Sedvall G., Halldin C., Swahn C.G., Farde L. Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man. Psychopharmacology. 121:1995;300-308.
105. Kaufman M.J., Madras B.K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse. 9:1991;43-49.
106. Kelly M.A., Rubinstein M., Asa S.L., Zhang G., Saez C., Bunzow J.R., Allen R.G., Hnasko R., Ben-Jonathan N., Grandy D.K., Low M.J. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 19:1997;103-113.
107. Khan Z.U., Mrzijak L., Gutierrez A., De la Caille A., Goldman-Rakic P.S. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA. 95:1998;7731-7736.
108. King G.R., Joyner C., Ellinwood E.H. Jr. Continuous or intermittent cocaine administration. effects of flupenthixol treatment during withdrawal Pharmacol Biochem Behav. 49:1994;883-889.
109. Kling-Petersen T., Ljung E., Svensson K. The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm. Pharmacol Biochem Behav. 49:1994;345-351.
110. Knable M.B., Egan M.F., Heinz A., Lee K.S., Coppola R., Weinberger D.R. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. Br J Psychiatry. 171:1997;574-577.
111. Kolloch R.E., Stumpe K.O., Ismer U., Kletzky O., DeQuattro V. Central dopaminergic mechanisms in young patients with essential hypertension. Clin Sci. 61(suppl. 7):1981;231s-234s.
112. Koob G.F., Bloom F.E. Molecular and cellular mechanisms of drug dependence. Science. 242:1988;715-723.
113. Kofman O.S. Are levodopa 'drug holidays' justified? Can J Neurol. 11(suppl. 1):1984;206-209.
114. Kuhar M.J. Recent biochemical studies of the dopamine transporter - a CNS drug target. Life Sci. 62:1998;1573-1575.
115. Kuno S., Mizuta E., Yamasaki S. Neuroleptic malignant syndrome in parkinsonian patients. risk factors Eur Neurol. 38:1997;56-59.
116. 3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav. 52:1995;503-508.
117. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (2)-3-(3-hydroxyphenyl)-N-N-propylpiperidine (Preclamol) in schizophrenia. Biol Psychiatry. 43:1998;2-11.
118. 2-family receptor distribution in human post-mortem tissue. An autoradiographic study Neuroreport. 6:1995;2505-2512.
119. 3 receptor agonist 7-OH-DPAT in rhesus monkeys trained to discriminate cocaine from saline. Psychopharmacology. 124:1996;306-314.
120. 3 receptor mRNA and binding sites in human brain. Mol Brain Res. 18:1993;187-192.
121. Lane P.L., Ross R. Intravenous chlorpromazine. preliminary results in acute migraine Headache. 25:1985;302-304.
122. Lane P.L., McLellan B.A., Baggoley C.J. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 18:1989;360-365.
123. Lang A.E., Lozano A.M. Parkinson's disease. N Engl J Med. 339:1998;1130-1143.
124. Langtry H.D., Clissold S.P. Pergolide. a review of its pharmacological properties and therapeutic potential in Parkinson's disease Drugs. 39:1990;491-506.
125. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Br Med J. 311:1995;1602-1607.
126. Leier C.V., Heban P.T., Huss P., Bush C.A., Lewis R.P. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation. 58:1978;466-475.
127. Lera G., Vaamonde J., Rodriguez M., Obeso J.A. Cabergoline in Parkinson's disease. Long-term follow up Neurology. 43:1993;2587-2590.
128. Lidow M.S., Goldman-Rakic P.S. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA. 91:1994;4353-4356.
129. Lidow M.S., Williams G.V., Goldman-Rakic P.S. The cerebral cortex. a case for a common site of action of antipsychotics Trends Pharmacol Sci. 19:1998;136-140.
130. Lipinski J.F., Sallee F.R., Jackson C., Sethuraman G. Dopamine agonist treatment of Tourette disorder in children. results of an open-label trial of pergolide Mov Disord. 12:1997;402-407.
131. Liu L.X., Monsma F.J. Jr., Sibley D.R., Chiodo L.A. D2L, D2S and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse. 24:1996;156-164.
132. Lokhandwala M.F., Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J. 5:1991;3023-3030.
133. Lokhandwala M.F., Vyas S.J., Hegde S.S. Renal dopamine and tubular DA-1 receptors in the regulation of sodium excretion. J Auton Pharmacol. 10(suppl. 1):1990;s31-s39.
134. Lundberg J., Lundberg D., Norgren L., Werner O. Dopamine counteracts hypertension during general anaesthesia and hypotension during thoracic epidural anesthesia for abdominal aortic surgery. J Cardiothorac Anesth. 4:1990;348-353.
135. MacDonald T.M., Jeffrey R.F., Freestone S., Lee M.R. Sulpiride antagonizes the renal effects of L-glutamyl-L-dopa in man. Br J Clin Pharmacol. 25:1988;203-212.
136. 9Gly polymorphism and schizophrenia. a haplotype relative risk study and association with clozapine response Mol Psychiatry. 3:1998;72-75.
137. 3 receptors. Mol Pharmacol. 365:1993;441-445.
138. Marik P.E., Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic shock. JAMA. 272:1994;1354-1357.
139. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 17(suppl. 2):1994;S32-S44.
140. Martin C., Papazian L., Perrin G., Saux P., Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest. 103:1993;1826-1831.
141. Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T. Full-length cDNA cloning and redistribution of human dopamine D4 receptor. Mol Brain Res. 29:1995;157-162.
142. Matta S.G.F. Metoclopramide in the treatment of migraine. Practitioner. 212:1974;887-890.
143. Meador-Woodruff J.H., Damask S.P., Watson J.J. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA. 91:1994;8297-8301.
144. Meltzer H., Sommers A., Luchins D. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol. 6:1986;329-338.
145. Mierau J., Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 215:1992;161-170.
146. Mierau J., Schneider F.J., Ensinger H.A., Chio C.L., Lajiness M.E., Huff R.M. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 260:1995;29-36.
147. Molho E.S., Factor S.A., Weiner W.J., Sanchez-Ramos J.R., Singer C., Shulman L., Brown D., Sheldon C. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl. 45:1995;225-230.
148. Montastruc J.L., Rascol O., Senard J.M. Current status of dopamine agonists in Parkinson's disease management. Drugs. 46(3):1993;384-393. Erratum: Drugs 52, 540 (1996).
149. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease. a five year follow up J Neurol Neurosurg Psychiatry. 57:1994;1034-1038.
150. Myles P.S., Buckland M.R., Schenk N.J., Cannon G.B., Langley M., Davis B.B., Weeks A.M. Effect of 'renal dose' dopamine on renal function following cardiac surgery. Anaesth Intensive Care. 21:1993;56-61.
151. 3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology. 125:1996;13-22.
152. 3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology. 46:1996;791-795.
153. Nash S.R., Godinot N., Caron M.G. Cloning and characterization of the opossum kidney cell D1 dopamine receptor. expression of identical D1A and D1B dopamine receptor mRNAs in opossum kidney and brain Mol Pharmacol. 44:1993;918-925.
154. Niebaver J., Coates A.J. Treating chronic heart failure. time to take stock Lancet. 349:1997;966-967.
155. Niznik H.B. Dopamine receptors. molecular structure and function Mol Cell Endocrinol. 54:1987;1-22.
156. Niznik H.B., Jarvie K.R., Brown E.M. Dopamine D1 receptors of the calf parathyroid gland. identification of a ligand binding subunit with lower apparent molecular weight but similar primary structure to neuronal D1-receptors Biochemistry. 28:1989;6925-6930.
157. O'Dowd B.F. Structures of dopamine receptors. J Neurochem. 60:1993;804-816.
158. Olanow C.W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., Shoulson I., Kurlan R., Grimes J.D., Jankovic J., Hoehn M., Markham C.H., Duvoisin R., Reinmuth O., Leonard H.A., Ahlskog E., Feldman R., Hershey L., Yahr M.D. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 9:1994;40-47.
159. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 38:1995;771-777.
160. Olanow C.W., Kordower J.H., Freeman T.B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19:1996;102-109.
161. 4 receptor. Sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol. 4:1992;137-146.
162. Ozono R., O'Connel D.P., Vaughan C., Bolkin S.J., Walk S.F., Felder R.A., Carey R.M. Expression of the subtype 1A dopamine receptor in the rat heart. Hypertension. 27:1996;603-703.
163. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 39:1996;29-36.
164. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease. Three year interim report Br Med J. 307:1993;469-472.
165. Patel S., Patel S., Marwood R., Emms F., Marston D., Leeson P.D., Curtis N.R., Kulagowski J.J., Freedman S.B. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol. 50:1996;1658-1664.
166. Perdue P.W., Balser J.R., Lipsett P.A., Breslow M.J. 'Renal dose' dopamine in surgical patients. Dogma or science? Ann Surg. 227:1998;470-473.
167. Perez-Aharon J., Abbot R.J., Playfer J.R.et al. Ropinirole, a placebo-controlled study of efficacy as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa. Neurology. 44(suppl. 2):1994;244.
168. 4 receptor gene and schizophrenia. Am J Med Genet. 60:1995;452.
169. Pezzoli G., Martignoni E., Pacchetti C., Angeleri V.A., Lamberti P., Muratorio A., Bonuccelli U., De Mari M., Foschi N., Cossutta E.et al. Pergolide compared to bromocriptine in Parkinson's disease. a multicentre, cross-over, controlled study Mov Disord. 9:1994;431-436.
170. Pfaffenrath V., Oestreich W., Haase W. Flunarizine (10 and 20 mg) i.v. versus placebo in the treatment of acute migraine attacks. a multi-centre double-blind study Cephalalgia. 10:1990;77-81.
171. Piccini P., Pavese N., Palombo C., Pittella G., Distante A., Bonuccelli U. Transcranial Doppler ultrasound in migraine and tension-type headache after apomorphine administrarion. double-blind crossover versus placebo study Cephalalgia. 15:1995;399-403.
172. Picetti R., Saiardi A., Abdel Samad T., Bozzi Y., Baik J.H., Borrelli E. Dopamine D2 receptors in signal transduction and behaviour. Crit Rev Neurobiol. 11:1997;121-142.
173. Pickar D., Breier A., Hsiao J.K., Doran A.R., Wolkowitz O.M., Pato C.N., Konicki P.E., Potter W.Z. CSF and plasma monoamine metabolites and their relation to psychosis. implications for regional brain dysfunction in schizophrenia Arch Gen Psychiatry. 47:1990;641-648.
174. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 21:1998;141-151.
175. 3 receptor-preferring agonist. comparison to other dopamine receptor agonists Eur J Pharmacol. 312:1996;35-44.
176. Pogue-Geile M., Ferrell R., Deka R., Debski T., Manuck S. Human novelty-seeking personality traits and dopamine D4 receptor polymorphisms. a twin and genetic association study Am J Med Genet (Neuropsychiatr Genet). 81:1998;44-48.
177. Rajfer S.I., Anton A.H., Rossen J., Goldberg L.I. Beneficial hemodynamic effects of oral levodopa in heart failure. relationship to the generation of dopamine N Engl J Med. 310:1984;1357-1362.
178. Ramdobr B., Schuren K.P., Biamino G., Schröder R. Der EinQuss von Dopamine auf Haemodynamik und Nierenfunktion bei der schweren Herzinsuffizienz des Menschen. Klin Wschr. 51:1973;549-556.
179. Rampello L., Nicoletti G., Raffaele R. Dopaminergic hypothesis for retarded depression. a symptom profile for predicting therapeutic responses Acta Psychiatr Scand. 84:1991;552-554.
180. Raner C., Biber B., Lundberg J., Martner J., Winso O. Cardiovascular depression by isoflurane and concomitant thoracic epidural anesthesia is reversed by dopamine. Acta Anaesthesiol Scand. 38:1994;136-143.
181. Rappaport M.S., Seafon S.C., Prikhozan A., Huntley G.W., Morrison J.H. Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum. Brain Res. 616:1993;242-250.
182. Rascol O., Lees A.J., Senard J.M., Pirtosek Z., Montastruc J.L., Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 19:1996;234-245.
183. Ren J.H., Unverferth D.V., Leier C.V. The dopamine congener, ibopamine, in congestive heart failure. J Cardiovasc Pharmacol. 6:1984;748-755.
184. Reynolds G.P., Mason S. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem. 63:1994;1576-1577.
185. Robbins T.W., Sahakian B.T. Animal models of mania. Belmaker R.H., Van Praag H.M. Mania. An Evolving Concept:1980;143-216 SP Medical & Scientific Books, New York.
186. Robinson T., Gariballa S., Fancourt G., Potter J., Castleden M. The acute effects of a single dopamine infusion in elderly patients with congestive heart failure. Br J Clin Pharmacol. 37:1994;261-263.
187. Rothman R.B. High affinity dopamine reuptake inhibitors as potential cocaine antagonists. a strategy for drug development Life Sci. 46:1990;17-21.
188. Rousseau M.F., Falgoso J., Van Eyll C., Van Mechelon H., Musso N.R., Lotti G., Pouleur H. Effects of epinephrine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovasc Pharmacol. 19:1992;155-162.
189. Russel M.B., Rasmussen B.K., Fenger K., Olesen J. Migraine without aura and migraine with aura are distinct clinical entities. a study of four hundred and eighty-four male and female migraineurs from the general population Cephalalgia. 16:1996;239-245.
190. Sabatini U., Rascol O., Rascol A., Montastruc J. Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients. Clin Neuropharmacol. 13:1990;264-267.
191. Sage J.I., Duvoisin R.C. Pergolide therapy in Parkinson's disease. a double-blind, placebo-controlled study Clin Neuropharmacol. 8:1985;260-265.
192. Saiardi A., Samad T.A., Picetti R., Bozzi Y., Baik J., Borrelli E. The physiological role of dopamine receptors. Adv Pharmacol. 42:1998;521-524.
193. Sallee F.R., Nesbitt L., Jackson C., Sine L., Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 154:1997;1057-1062.
194. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology. 135:1998;182-193.
195. Sandrini M., Benelli A., Baraldi M. Evidence that dopamine receptors identified by [3H]dopamine in the ventricles of guinea-pig heart are of DA2 type. Pharmacol Res Commun. 18:1986;1151-1157.
196. +-ATPase regulation by protein kinases in the proximal and distal nephron. Am J Physiol. 265:1993;F399-F405.
197. Schachter M., Marsden C.D., Parkes J.D., Jenner P., Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry. 43:1980;1016-1021.
198. Schaer G.L. Norepinephrine plus low-dose dopamine. a beneficial combination Crit Care Med. 28:1998;205.
199. Schlachter S.K., Poel T.J., Lawson C.F., Dinh D.M., Lajiness M.E., Romero A.G., Rees S.A., Duncan J.N., Smith M.W. Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol. 322:1997;283-286.
200. Schwartz J., Giro B., Martres M.P., Sokoloff P. The dopamine receptor family. molecular biology and pharmacology Neuroscience. 4:1992;99-108.
201. 3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum. correlation with the stimulant properties of ritalinic acid esters J Neurochem. 45:1985;1062-1070.
202. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
203. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
204. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci. 86:1989;10156-10160.
205. Seeman P., Guan H.C., van Tol H. Dopamine D4 receptor elevated in schizophrenia. Nature. 365:1993;441-445.
206. Seeman P., Ulpian C., Chouinard G., Van Tol H.H., Dwosh H., Lieberman J.A., Siminovitch K., Liu I.S., Waye J., Voruganti P., Hudson C., Serjeant G.R., Masibay A.S., Seeman M.V. Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians. No association with schizophrenia Am J Med Genet. 54:1994;384-390.
207. Seri I. Cardiovascular, renal, and endocrine actions of dopamine in neonates and children. J Pediatr. 126:1995;333-344.
208. Serra G., Argiolas A., Fadda F., Melis M.R., Gessa G.L. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of antidepressants on dopamine synthesis and motor activity. Life Sci. 25:1979;415-424.
209. Serra G., Collu M., Gessa G.L. Yawning is elicited by D2 dopamine agonists but is blocked by the D1 antagonist, SCH 23390. Psychopharmacology. 91:1987;330-333.
210. Sesack S.R., Aoki C., Pickel V.M. Ultrastructural localisation of D2-receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci. 14:1994;88-106.
211. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med. 27:1997;1247-1256.
212. Shapiro E., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J., Phillips R.A. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 46:1989;722-730.
213. Sicuteri F., Boccuni M., Fanciullacci M., D'Egidio P., Bonciana M. A new nonvascular interpretation of syncopal migraine. Adv Neurol. 33:1982;199-208.
214. 5 dopamine receptors. Neuroscience. 82:1998;1095-1101.
215. Silverstone T. Dopamine in manic-depressive illness. J Affect Disord. 8:1985;225-231.
216. Singer H.S., Buffer I.J., Tune L.E., Seifert W.E., Coyle J.T. Dopaminergic dysfunction in Tourette syndrome. Ann Neurol. 12:1982;361-366.
217. Singer H.S., Hahn I.H., Moran T.H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol. 30:1991;558-562.
218. Smit A.J. Dopamine and the kidney. Neth J Med. 34:1989;47-58.
219. Smit A.J., Girbes A.R.J. Dopamine agonists in heart failure. An untimely death Neth J Med. 51:1997;151-153.
220. Smit A.J., Meijer S., Wesseling H., Reitsma W.D., Donkeer A.J. Impaired renal hemodynamic but conserved natriuretic response to dopamine in patients with renal disease. Nephron. 52:1989;338-346.
221. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (Lond). 347:1990;146-151.
222. Soyaka D., Taneri Z., Oestreich W., Schmidt R. Flunarizine i.v. in the acute treatment of common or classic migraine attacks. a placebo-controlled double-blind trial Headache. 29:1989;21-27.
223. Spanagel R., Hertz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 89:1992;2046-2050.
224. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci. 16:1996;6100-6106.
225. Stricker B.H., Feenstra J., Ottervanger J.P., Porsius A.J., Grobbee D.E. A nested case-control study on mortality in users of ibopamine. Neth J Med. 51:1997;163-168.
226. Sullivan P.F., Fifield W.J., Kennedy M.A., Mulder R.T., Sellman J.D., Joyce P.R. No association between novelty seeking and the type 4 dopamine receptor gene (DRD4) in two new Zealand samples. Am J Psychiatry. 155:1998;98-101.
227. Swanson J.M., Sunohara G.A., Kennedy J.L., Regino R., Fineberg E., Wigal T., Lerner M., Williams L., LaHoste G.J., Wigal S. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD). a family-based approach Mol Psychiatry. 3:1998;38-41.
228. Tamminga C.A., Cascella N.G., Lahti R.A., Lindberg M., Carlsson A. Pharmacological properties of (-)-3PPP (preclamol) in man. J Neural Trans. 88:1992;165-175.
229. Tek D.S., McClellan D.S., Olshaker J.S., Allen C.L., Arthur D.C. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 19:1990;1083-1087.
230. Ter Wee P.M., Smit A.J., Rosman J.B., Sluiter W.J., Donker A.J.M. Effect of intravenous infusion of low-dose dopamine on renal function in normal individuals and in patients with renal disease. Am J Nephrol. 6:1986;42-46.
231. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.
232. Thierry A.M., Pirot S., Gioanni Y., Glowinski J. Dopamine function in the prefrontal cortex. Adv Pharmacol. 42:1998;717-720.
233. Trekova N.A., Dementyeva I.I., Dzemeshkevich S.L., Asmangulyan Ye T. Blood oxygen transport function in cardiopulmonary bypass surgery for acquired heart valvular diseases. Int Surg. 79:1994;60-64.
234. Vaamonde J., Luquin M.R., Obeso J.A. Subcutaneous lisuride infusion in Parkinson's disease; response to chronic administration in 34 patients. Brain. 114:1991;601-614.
235. van de Borne P., Oren R., Somers V.K. Dopamine depresses minute ventilation in patients with heart failure. Circulation. 98:1998;126-131.
236. Van den Berghe G., de Zegher F., Lauwers P., Veldhuis J.D. Luteinizing hormone secretion and hypoandrogenaemia in critically ill men. Effect of dopamine Clin Endocrinol. 41:1994;563-569.
237. 4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
238. Verhagen M.L., Sethy V.H., Roberts J.R., Bravi D., Hoff J., Mouradian M.M., Chase T.N. Motor effects of the partial dopamine agonist (-)-3-PPP (Preclamol) in Parkinson's disease. Neurology. 44(suppl. 2):1994;244.
239. Vidailhet M.J., Bonnet A.M., Belal S., Dubois B., Marle C., Agid Y. Ropinirole without levodopa in Parkinson's disease. Lancet. 336:1990;316-317.
240. Vincent J.L. Towards improving vital organ function. assessing the role of dopexamine hydrochloride in intensive care medicine Clin Int Care. 2(suppl.):1991;5-54.
241. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Virkun S., Logan J., Gatley S.J., Pappas N., Hitzemann R., Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 386:1997;827-830.
242. Vyas S.J., Eichberg J., Lokhandwala M.F. Characterization of receptors involved in dopamine-induced activation of phospholipase C in rat renal cortex. J Pharmacol Exp Ther. 260:1992;134-139.
243. Waelkens J. Dopamine blockade with domperidone. Bridge between prophylactic and abortive treatment of migraine? A dose-finding study Cephalalgia. 4:1984;85-90.
244. Weiner D.M., Levey A.I., Sunahara R.K., Niznik H.B., O'Dowd B.F., Seeman P., Brann M.R. D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA. 88:1991;1859-1863.
245. Weinshank R.L., Adham N., Macchi M., Olsen M.A., Branchek T.A., Hartig P.R. Molecular cloning and characterization of a high affinity dopamine receptor (D1 beta) and its pseudogene. J Biol Chem. 266:1991;22427-22435.
246. Williams M., Wright S., Lloyd G.K. Improved therapies for Parkinson's disease. life beyond dopamine D2/D3 receptor agonists Trends Pharmacol Sci. 18:1997;307-310.
247. Willner P., Scheel-Kruger J. The Mesolimbic Dopamine System. From Motivation to Action:1991;John Wiley & Sons, Chichester.
248. Wolters E.C., Tissingh G., Bergmans P.L., Kuiper M.A. Dopamine agonists in Parkinson's disease. Neurology. 45(suppl. 3):1995;S28-S34.
249. Wright C.E., Sisson T.L., Ichhpurani A.K., Peters G.R. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 37:1997;520-525.
250. 1B) expression in rat renal microvessels. Pediatr Res. 37:1995;374A.
251. Yamaguchi I., Jose P.A., Mouradian M.M., Canessa L.M., Monsma F.J. Jr., Sibley D.R., Takeyasu K., Felder R.A. Expression of dopamine D1A receptor gene in proximal convoluted tubule of rat kidneys. Am J Physiol. 264:1993;F280-F285.
252. 1A receptors in rat juxtaglomerular cells. Hypertension. 29:1997;962-968.
253. 1 receptor agonist, in a canine model of acute congestive heart failure. Gen Pharmacol. 30:1998;733-737.
254. Zaritsky A.L. Catecholamines, inotropic medications, and vasopressor agents. Chernow B. The Pharmacologic Approach to the Critically Ill Patients. 1994;387-404 Williams & Wilkins, Baltimore.
255. Zaritsky A.L., Lotze A., Stull R., Goldstein D.S. Steady-state dopamine clearance in critically ill infants and children. Crit Care Med. 16:1988;217-220.
256. Zenner M.T., Nobile M., Henningsen R., Smeraldi E., Civelli O., Hartman D.S., Catalano M. Expression and characterization of a dopamine D4R variant associated with delusional disorder. FEBS Lett. 422:1998;146-150.